Drug Profile
Soticlestat - Takeda
Alternative Names: OV-935; TAK 935Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator Takeda
- Developer Ovid Therapeutics; Takeda
- Class Analgesics; Antiepileptic drugs; Heterocyclic compounds; Piperidines; Pyridines; Small molecules
- Mechanism of Action Cholesterol 24-hydroxylase inhibitors; NMDA receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dravet syndrome; Lennox-Gastaut syndrome
- Phase II Complex regional pain syndromes; Epilepsy; Myoclonic epilepsies; Tuberous sclerosis
- Phase I Liver failure
Most Recent Events
- 25 Jan 2024 Takeda completes a phase III SKYWAY trial in Lennox-Gastaut syndrome (Adjunctive treatment, In adolescents, In children, In adults) in Spain, Greece, Japan, the Netherlands, Hungary, USA, Australia, Belgium, Canada, China, France, Italy, Latvia, Mexico, Poland, Russia, Serbia, Spain, Ukraine, United Kingdom, South Korea, Brazil and Germany (PO, tablet) (NCT04938427)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Complex-regional-pain-syndromes(In volunteers) in Japan (PO, Tablet)
- 07 Jul 2023 Takeda completes a phase I trial (In volunteers) in USA (PO) (NCT05602818)